156 related articles for article (PubMed ID: 22935698)
1. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.
Iwai A; Bourboulia D; Mollapour M; Jensen-Taubman S; Lee S; Donnelly AC; Yoshida S; Miyajima N; Tsutsumi S; Smith AK; Sun D; Wu X; Blagg BS; Trepel JB; Stetler-Stevenson WG; Neckers L
Cell Cycle; 2012 Oct; 11(19):3649-55. PubMed ID: 22935698
[TBL] [Abstract][Full Text] [Related]
2. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
3. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mollapour M; Tsutsumi S; Donnelly AC; Beebe K; Tokita MJ; Lee MJ; Lee S; Morra G; Bourboulia D; Scroggins BT; Colombo G; Blagg BS; Panaretou B; Stetler-Stevenson WG; Trepel JB; Piper PW; Prodromou C; Pearl LH; Neckers L
Mol Cell; 2010 Feb; 37(3):333-43. PubMed ID: 20159553
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
[TBL] [Abstract][Full Text] [Related]
5. Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability.
Lokeshwar VB
Cell Cycle; 2012 Oct; 11(20):3722-3. PubMed ID: 22983000
[No Abstract] [Full Text] [Related]
6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
7. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
8. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
9. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1.
Goes FS; Martin J
Eur J Biochem; 2001 Apr; 268(8):2281-9. PubMed ID: 11298745
[TBL] [Abstract][Full Text] [Related]
11. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.
Redlak MJ; Miller TA
Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984
[TBL] [Abstract][Full Text] [Related]
12. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
14. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
17. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.
Powers MV; Valenti M; Miranda S; Maloney A; Eccles SA; Thomas G; Clarke PA; Workman P
Oncotarget; 2013 Nov; 4(11):1963-75. PubMed ID: 24185264
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 phosphorylation, Wee1 and the cell cycle.
Mollapour M; Tsutsumi S; Neckers L
Cell Cycle; 2010 Jun; 9(12):2310-6. PubMed ID: 20519952
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone.
Yano A; Tsutsumi S; Soga S; Lee MJ; Trepel J; Osada H; Neckers L
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15541-6. PubMed ID: 18840695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
